Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other Accumulated Expenses (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Other Accumulated Expenses for 6 consecutive years, with $849778.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 62.91% year-over-year to $849778.0, compared with a TTM value of $849778.0 through Dec 2025, up 62.91%, and an annual FY2025 reading of $849778.0, up 62.91% over the prior year.
  • Other Accumulated Expenses was $849778.0 for Q4 2025 at SAB Biotherapeutics, up from $649957.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.7 million in Q3 2024 and bottomed at $200000.0 in Q1 2023.
  • Average Other Accumulated Expenses over 5 years is $505329.1, with a median of $364478.0 recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 708.69% in 2024, then tumbled 61.73% in 2025.
  • Year by year, Other Accumulated Expenses stood at $283909.0 in 2021, then skyrocketed by 80.73% to $513110.0 in 2022, then fell by 28.97% to $364478.0 in 2023, then soared by 43.12% to $521639.0 in 2024, then soared by 62.91% to $849778.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for SABS at $849778.0 in Q4 2025, $649957.0 in Q3 2025, and $699133.0 in Q2 2025.